-
Innovation Ranking
NewInnovation Ranking – Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Erwinaze (asparaginase erwinia chrysanthemi), Defitelio (defibrotide sodium), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells...
-
Product Insights
NewNet Present Value Model: Jazz Pharmaceuticals Plc’s Suvecaltamide Hydrochloride
Empower your strategies with our Net Present Value Model: Jazz Pharmaceuticals Plc's Suvecaltamide Hydrochloride report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Jazz Pharmaceuticals Plc’s Zanidatamab
Empower your strategies with our Net Present Value Model: Jazz Pharmaceuticals Plc's Zanidatamab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
NewPharma M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Pharma Sector
-
Product Insights
NewNet Present Value Model: Amgen Inc’s Tarlatamab
Empower your strategies with our Net Present Value Model: Amgen Inc's Tarlatamab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Jazz Pharmaceuticals Plc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Jazz Pharmaceuticals Plc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Orthodontic Materials and Products Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Orthodontic Materials and Products Pipeline Market Report Overview Orthodontic materials and products are designed to correct teeth and jaws that are positioned improperly. The orthodontic materials and products pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GWP-42006 in Partial Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GWP-42006 in Partial Seizure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GWP-42006 in Partial Seizure Drug Details: GWP-42006 (CBDV, cannabidivarin) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRA-052 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRA-052 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRA-052 in Ulcerative Colitis Drug Details: PRA-052 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Suvecaltamide Hydrochloride in Myoclonic Seizure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Suvecaltamide Hydrochloride in Myoclonic Seizure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Suvecaltamide Hydrochloride in Myoclonic Seizure Drug Details: JZP-385 (CX-8998) is under...